As some of you may know, I have been expanding my investments to include newly gained knowledge from experiences with HCV. One of the many related companies I invested in sent me a letter some might find interesting.
My PI's have more potential, but... it was dirt cheap, and had promise like many of my stocks that have taken the ride from the bottom up. Got in at .11 and it closed at .16 last I looked. I will hold it till it goes out or up.
Check this letter out. Ya Never know...
Dear Shareholder,
In 1957 two scientists in England noted a substance in chicken embryos
that was "interfering" with the growth of influenza virus. The scientists
isolated the protein and called it "interferon." In other words, it has
been known for 52 years that interferon blocks influenza virus. We have
prepared a more technical summary of a portion of the data that shows that
interferon prevents or effectively treats influenza in ferrets, mice,
guinea pigs and humans:
(http://amarbio.com/index.php?option=com_content&view=article&id=22&Itemid=44).
(http://www.cdc.gov/ncidod/EID/vol10no2/03-0482.htm)
There is additional animal data presently being generated by a colleague
in Germany, and Dr. Manfred Beilharz (the principal investigator of our
ongoing interferon flu study in Australia) and I both believe that the
existing animal and human data should motivate national and international
health authorities to consider low dose oral interferon for the prevention
and treatment of influenza.
Because of the current influenza outbreak, it is important that health
officials recognize that oral interferon represents an inexpensive,
non-toxic, easy-to-administer oral therapy for flu. Our interferon
lozenges are stable at room temperature for up to 2 years so the therapy
lends itself to the healthcare needs of the developing world where
refrigeration may not be readily available.
The government approved anti-viral drugs are not a long term solution
because the influenza virus has the capability of rapidly developing
resistance to the drugs according to JAMA, Vol. 301, No. 10, Pages
1034-1041, May 2009. Because interferon acts indirectly by boosting the
immune system, influenza viruses have not developed resistance to
interferon, but instead have developed strategies to shut host cell
production of interferon. Therefore, treating with extra interferon to
overcome the viral strategy makes scientific sense.
Interferon is a protein produced naturally in mammals, fish, birds,
reptiles and amphibians. Interferon helps regulate the immune system of
all animals. Interferon is not a miracle drug but instead interferon can
boost the body's natural immune system. Properly used, interferon can
help the immune system to perform more efficiently.
The clinical data from our flu study in Australia will be available this
fall. Based on our previous work with cattle, there is every reason to
believe that oral interferon lozenges will be successful at preventing and
lessening the severity of influenza infection in the study's volunteers.
We need to make plans now for a follow-up flu study in the U.S., rather
than waiting for the final data from Australia.
We are working diligently to launch an interferon flu study in the U.S.
The brewing swine flu outbreak is motivating health officials to examine
every possible weapon against an international flu pandemic; we are
hopeful that this will include a thorough study of oral interferon which
will prove that it is a safe and effective treatment.
Yours sincerely,
Dr. Joseph Cummins,
President and CEO Amarillo Biosciences, Inc.